Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).

被引：5
|
作者：
Andre, Fabrice
Hamilton, Erika P.
Loi, Sherene
Schmid, Peter
Anders, Carey K.
Yu, Tinghui
Boston, Sarice
D'Cruz, Celina M.
Herbolsheimer, Pia
Jhaveri, Komal L.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS1096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1096
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Kolberg, Hans-Christian
    Andre, Fabrice
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Anders, Carey
    Yu, Tinghui
    Boston, Sarice
    D'cruz, Celina
    Herbolsheimer, Pia
    Jhaveri, Komal
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 32 - 32
  • [2] Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Andre, Fabrice
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Yu, Tinghui
    Lu, Shiyao
    Boston, Sarice
    D'Cruz, Celina
    Herbolsheimer, Pia
    Jhaveri, Komal
    CANCER RESEARCH, 2021, 81 (04)
  • [3] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
    Jhaveri, Komal
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Darilay, Annie
    Gao, Chen
    Patel, Gargi
    Wrona, Magdalena
    Andre, Fabrice
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINYBreast08)
    Jhaveri, Komal
    Andre, Fabrice
    Hamilton, Erika
    Schmid, Peter
    Anders, Carey
    Testa, Laura
    Ganshina, Inna
    Lu, Yen-Shen
    Im, Seock-Ah
    Young, Robyn
    Wrona, Magdalena
    Lloyd, Caron
    Zhang, Yiwen
    Loi, Sherene
    CANCER RESEARCH, 2024, 84 (09)
  • [5] A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer
    Hsieh, Y. Pei
    ANNALS OF ONCOLOGY, 2024, 35 : S1394 - S1394
  • [6] DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2+mBC
    Andre, Fabrice
    Hamilton, Erika P.
    Loi, Sherene
    Anders, Carey K.
    Schmid, Peter
    Stroyakovskiy, Daniil
    Villanueva, Rafael
    Pedrini, Jose Luiz
    Doval, Dinesh Chandra
    Zurawski, Bogdan
    Chen, Shin-Cheh
    Boston, Sarice Renee
    Konpa, Adam
    Pierotti, Barbara
    Fabbri, Giulia
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
    Hamilton, Erika
    Shapiro, Charles L.
    Petrylak, Daniel
    Boni, Valentina
    Martin, Miguel
    Del Conte, Gianluca
    Cortes, Javier
    Agarwal, Laila
    Arkenau, Hendrik-Tobias
    Tan, Antoinette R.
    Debruyne, Philip
    Minchom, Anna
    Rutten, Annemie
    Valdes-Albini, Frances
    Yu, Evan Y.
    Augustine, Bincy
    D'Amelio, Anthony, Jr.
    Barrios, Daniel
    Hurvitz, Sara A.
    CANCER RESEARCH, 2021, 81 (04)
  • [8] [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 7 - 9
  • [9] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
    Krop, Ian E.
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Modi, Shanu
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)
    Hamilton, Erika
    Jhaveri, Komal
    Loi, Sherene
    Anders, Carey
    Schmid, Peter
    Penkov, Konstantin
    Artamonova, Elena
    Zhukova, Lyudmila
    Stroyakovsky, Daniil L.
    Doval, Dinesh Chandra
    Villanueva, Rafael
    Michelini, Flavia
    Chandarlapaty, Sarat
    Wilson, Matt
    Boston, Sarice R.
    Konpa, Adam
    Mondal, Shoubhik
    Andre, Fabrice
    CANCER RESEARCH, 2023, 83 (05)
12345